Table 2.
Safety and efficacy of pretreatment oral APT in all patients
| Characteristics | All patients (n=915) | Non-APT (n=716) | APT | P value* | P value† | ||
| Total (n=199) | SAPT (n=137) | DAPT (n=62) | |||||
| Postoperative haemorrhage | |||||||
| sICH | 51 (5.6) | 44 (6.1) | 7 (3.5) | 3 (2.2) | 4 (6.5) | 0.153 | 0.114 |
| Recanalisation status | |||||||
| Successful recanalisation mTICI 2b/3 | 838 (91.6) | 650 (90.8) | 188 (94.5) | 128 (93.4) | 60 (96.8) | 0.097 | 0.135 |
| Complete recanalisation mTICI 3 | 642 (70.2) | 488 (68.2) | 154 (77.4) | 111(81) | 43 (69.4) | 0.012 | 0.01 |
| Functional outcome at 3 months | |||||||
| Excellent outcome (mRS 0–1) | 382 (41.7) | 294 (41.1) | 88 (44.2) | 53 (38.7) | 35 (56.5) | 0.424 | 0.046 |
| Functional independence (mRS 0–2) | 473 (51.7) | 372(52) | 101 (50.8) | 62 (45.3) | 39 (62.9) | 0.764 | 0.067 |
| Mortality (mRS 6) | 160 (17.5) | 127 (17.7) | 33 (16.6) | 30 (21.9) | 3 (4.8) | 0.704 | 0.004 |
*P value between non-APT and APT group.
†P value between non-APT, SAPT and DAPT group.
APT, antiplatelet; DAPT, dual antiplatelet; mRS, modified Rankin score; mTICI, modified treatment in cerebral infarction; SAPT, single antiplatelet; sICH, symptomatic intracranial haemorrhage.